^
    Back
    Association details:
    Biomarker:IL1RAP overexpression
    Cancer:Pancreatic Ductal Adenocarcinoma
    Drug:nadunolimab (CAN04) (IL1RAP inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    AACR 2023
    Title:

    2172 / 14 - Tumor IL1RAP levels and reduction in serum biomarkers correlate with response in PDAC patients treated with nadunolimab, an anti-IL1RAP monoclonal antibody, in combination with gemcitabine and nab-paclitaxel

    Published date:
    03/15/2023
    Excerpt:
    Patients with previously untreated, locally advanced or metastatic PDAC received nadunolimab at doses from 1 to 7.5 mg/kg, in combination with gemcitabine and nab-paclitaxel (GN)…The data suggest a relationship between high IL1RAP expression and increased iPFS and OS.
    Secondary therapy:
    gemcitabine + paclitaxel